The US Food and Drug Administration has reported shortages of the GLP-1 medications Ozempic, Wegovy and Mounjaro at various dosages over the past year as drugmakers have raced to keep up with skyrocketing demand
They have proven highly effective for managing blood sugar levels and helping with weight loss
Although semaglutide (Ozempic/Wegovy) has largely overtaken liraglutide in clinical preference due to its weekly dosing and greater weight loss efficacy, liraglutide retains several advantages: it has over 15 years of post-marketing safety data, cardiovascular outcome data from the landmark LEADER trial, and pediatric approvals for both diabetes and obesity
[16] [17] Whether these risks apply to retatrutide specifically is not yet established, as the full long-term safety profile remains unknown pending Phase 3 data
Repeated injection at the same location causes lipohypertrophy, a thickening of the subcutaneous fat tissue that creates firm lumps under the skin
Peptides, 163 , Article 170974